PubMed Health⌕ Search

Biomedical subjects

S Shimasaki

Publications and source records attributed to S Shimasaki.

At least 55 records · Page 3Linked to original sources
PubMed1993

Regulation of insulin-like growth factor binding proteins in ovarian cancer cells by oestrogen.

Insulin-like growth factor-I (IGF-I), its receptor and its binding proteins are expressed by ovarian cancer cells. In this study, we examined oestradiol (E2) regulation of IGF-I and IGF binding proteins (IGFBP) in an oestrogen-responsive ovarian cancer cell line, PE04. In serum-free conditions, PE04 cell monolayer growth was increased 1.64-fold by 3 nmol/l E2 compared with controls, although IGF-I mRNA levels were not increased. In contrast to IGF-I mRNA, IGFBP mRNA was regulated by E2. E2 caused a marked decrease in IGFBP-3 RNA, but IGFBP-2, -4 and -6 levels were only minimally depressed. IGFBP-5 mRNA levels were increased by E2. Tamoxifen had less effect on IGFBP mRNA regulation. Ligand blotting showed that E2 reduced IGFBP levels in conditioned media. IGFBP RNA was also detected in human ovarian tissue samples. Thus, IGFBP expression can be regulated in oestrogen-responsive ovarian cancer by E2.

Blotting, Western↗
PubMed1993

Development of specific antibodies to rat insulin-like growth factor-binding proteins (IGFBP-2 to -6): analysis of IGFBP production by rat granulosa cells.

Six insulin-like growth factor-binding proteins (IGFBPs) have been isolated and their cDNAs cloned in the rat and human species. The next step is to develop antibodies to each IGFBP. Toward this goal, we generated rabbit polyclonal antibodies to rat IGFBP-2, -4, -5, and -6, using synthetic peptide fragments of the IGFBPs. A rat IGFBP-3 polyclonal antibody was prepared in a previous study using the native protein. Western immunoblotting demonstrated that the IGFBP-2, -3, -4, -5, and -6 antibodies were highly specific for their respective antigens. The elicited antisera were used to study IGFBP production in primary cultures of rat granulosa cells grown in serum-free medium for 72 h. Ligand blotting with 125I-labeled IGF-I and IGF-II revealed two bands migrating at 29 and 24 kilodaltons (kDa) in the medium of untreated control cells, whereas no bands were detectable in medium from cells incubated with 100 ng/ml FSH. Western blotting of control medium with all of the IGFBP antibodies revealed that the IGFBP-4 antibody stained two bands at 28 and 24 kDa, and the IGFBP-5 antibody stained two bands at 30 and 29 kDa. By contrast, these bands were absent in medium from FSH-stimulated cells; instead, two lower molecular mass bands of 21.5 and 17.5 kDa were detected with the IGFBP-4 antibody, and a 21-kDa band was seen with the IGFBP-5 antibody. The same 21.5- and 17.5-kDa bands were seen when exogenously added IGFBP-4 was incubated with the FSH-conditioned medium, whereas untreated medium did not degrade the added IGFBP-4. Incubation with the conditioned medium also degraded exogenous IGFBP-5 to yield a 21-kDa band. By contrast, medium from control cells did not degrade the exogenous IGFBP-5. This finding indicates that FSH induced the production of a protease from granulosa cells that degraded IGFBP-4 and -5 in the culture medium. No IGFBPs were detectable in medium from control or FSH-treated cells using the IGFBP-2, -3, and -6 antibodies. Northern blotting analysis of the same control granulosa cell cultures revealed a 2.6-kilobase and a 6.0-kilobase transcript for IGFBP-4 and -5, respectively; however, the IGFBP-4 and -5 mRNAs were essentially undetectable in FSH-treated cell cultures. To determine the effects of the IGFBPs on steroidogenesis, dose-response experiments were performed with IGFBP-4 and -5.(ABSTRACT TRUNCATED AT 400 WORDS)

Amino Acid Sequence↗
PubMed1993

Effects of estrous cycle stage and pregnancy on follistatin gene expression and immunoreactivity in rat reproductive tissues: progesterone is implicated in regulating uterine gene expression.

Follistatin, a monomeric protein originally isolated from ovarian follicular fluid, is now believed to be a major local regulator of the multifaceted actions of activin by virtue of its activin-binding properties. In view of the ability of follistatin to stimulate progesterone production from granulosa cells and its presence in newly formed corpora lutea, the following study was conducted to determine the effects of cycle stage and pregnancy on follistatin gene expression and immunoreactivity in the rat ovary and uterus with the intent of gaining additional insights into the regulation of follistatin in these tissues. Decidua and placentas were also examined on days 15, 18, and 21 of pregnancy. Follistatin messenger RNA (mRNA) levels were quantified using a sensitive solution hybridization-RNase protection assay and values normalized to the amount of cyclophilin mRNA present in each sample. Levels of follistatin-like immunoreactivity (FLI) in serum and tissues were estimated using a homologous porcine follistatin RIA. Follistatin message levels in the ovary increased between proestrus and estrus with a return to proestrous values on both days of diestrus. In the nonpregnant uterus, mRNA levels on proestrus were similar to levels measured in uteri taken from hypophysectomized or ovariectomized rats. Interestingly, follistatin gene expression increased almost 3-fold between proestrus and estrus. An additional experiment demonstrated that this increase could be abated by treatment of proestrous rats with pentobarbital which blocks preovulatory rises in serum progesterone levels and could be restored by administration of progesterone to pentobarbital-treated proestrous rats. In pregnant rats, ovarian follistatin message levels on days 3 and 6 of pregnancy were identical to levels observed on day 2 of diestrus. However, an abrupt 4-fold increase in ovarian mRNA levels occurred between days 6 and 9 with a further 58% increase occurring by day 12. This marked increase in message levels was unaccompanied by changes in ovarian FLI levels. A precipitous decrease in transcript levels accompanied by a decline in FLI levels then followed with ovarian gene expression on days 15 through 21 being slightly higher than expression during the initial stages of gestation. Expression of the gene in the decidua and placenta did not vary between days 15 and 21 of pregnancy. Levels of FLI in serum also were invariant during the cycle and pregnancy.(ABSTRACT TRUNCATED AT 400 WORDS)

Amino Acid Isomerases↗
PubMed1993

Expression and regulation of insulin-like growth factor-binding protein-1, -2, -3, and -4 messenger ribonucleic acids in purified rat Leydig cells and their biological effects.

The actions of insulin-like growth factor-I (IGF-I) are modified by binding proteins [IGF-binding proteins (IGFBPs)]. Previously, we reported that IGF-I enhances Leydig cell steroidogenesis and that IGF-I mRNA is expressed in Leydig cells. In the present study, we evaluated the expression and regulation of IGFBP-1, -2, -3, and -4 in purified rat Leydig cells and their biological effects. We found that none of the testicular crude interstitial cells, purified Leydig cells, or seminiferous tubules expressed IGFBP-1 mRNA. This indicated that IGFBP-1 mRNA is not expressed in the testis in detectable amounts. In contrast, large amounts of IGFBP-2 with a size of 1.8 kilobases (kb) were expressed in purified Leydig cells, and lesser amounts in crude interstitial cells. Small amounts of IGFBP-2 mRNA were expressed in seminiferous tubules, but none could be detected in liver. IGFBP-3 mRNA was predominantly expressed in purified Leydig cells, crude interstitial cells, and liver, while appreciable amounts were not found in seminiferous tubules. Liver had the highest amounts of IGFBP-4 mRNA, whereas purified Leydig cells and crude interstitial cells had lesser amounts. We next evaluated the pituitary dependency of IGFBP mRNAs in Leydig cells. Purified Leydig cells were isolated from 50-day-old rats 5 days after hypophysectomy. IGFBP-2, -3, and -4 mRNA levels in Leydig cells decreased 22%, 80%, and more than 90%, respectively, after hypophysectomy. In the liver, however, IGFBP-2 mRNA levels increased, and IGFBP-3 mRNA levels decreased, while IGFBP-4 remained unchanged. As expected, hypophysectomy caused decrements in large (7.0- to 7.5-kb; a 75% reduction) and small (0.8- to 1.2-kb; a 90% reduction) IGF-I mRNA levels in Leydig cells. Hypophysectomy also reduced IGF-I mRNA expression in liver. Finally, the effects of IGFBP-2, -3, and -4 on Leydig cell testosterone formation were investigated. hCG in a concentration of 10 ng/ml increased testosterone formation from 0.6 +/- 0.01 to 27.4 +/- 1.01 ng/10(6) cells.h. In the presence of IGF-I (10 ng/ml), testosterone formation was further increased to 58.6 +/- 1.6 ng/10(6) cells.h (P < 0.01). IGFBP-3 (0.1, 1, and 2.5 pmol/ml) caused a dose-dependent inhibition of IGF-I- plus hCG-induced testosterone formation. IGFBP-3 in a concentration of 2.5 pmol/ml completely neutralized the effects of IGF-I on Leydig cell steroidogenesis. IGFBP-4 had a lesser effect, while IGFBP-2 had no effect on IGF-I- plus hCG-induced testosterone formation.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗
PubMed1993

Insulin-like growth factor binding protein-3 gene expression is restricted to involuting corpora lutea in rat ovaries.

There is evidence that insulin-like growth factor binding protein-3 (IGFBP-3) is a part of the intrinsic IGF system in rat CL. Here, we examined when during luteogenesis the IGFBP-3 gene is expressed. IGFBP-3 messenger RNA (mRNA) was characterized by Northern analysis and in situ hybridization techniques. Animals were selected at proestrus (P 1000 h and P 2000 h), estrus (E 0200 h and E 1000 h), diestrus I (DI 1100 h), and diestrus II (DII 1100 h), and in pregnancy (day 12, before luteolysis and day 21, during luteolysis). A single 2.6 kilobase IGFBP-3 transcript was identified at each stage of the estrous cycle; however, the amounts of message varied markedly, being most abundant at P 1000 h, least abundant at P 2000 h, E 0200 h, E 1000 h, and DI, and then more abundant at DII. Corroborating our earlier report, IGFBP-3 mRNA was limited solely to corpora lutea (CL). Newly-formed CL-I at E 0200 h and E 1000 h revealed no IGFBP-3 hybridization. This is the period of early luteinization when cells undergo hypertrophy and capillaries and lymphatics penetrate the granulosa lutein layer. At DI 1100 h, a few cells (12.2 +/- 3.4%) near the central cavity of the CL-I showed a positive hybridization signal for IGFBP-3; this period is commensurate with active luteinization when the vascular tissue develops a distinctly sinusoidal character and progesterone secretion by CL-I increases. At DII 1100 h, more cells in the central area were positive for IGFBP-3 (55.2 +/- 6.4%); this is the period of active luteolysis when P4 secretion has fallen to basal levels. At P 1000 h, a positive IGFBP-3 hybridization signal was detected in most CL-I cells (85.3 +/- 2.8%), and the signal was particularly intense in subtypes of endothelial cells lining venous sinusoids and/or lymphatics and some perivascular cells; this is the period when patches of pyknotic cells appear in the central area of CL-I. At P 2000 h, 45.9 +/- 1.6% of the CL-I cells showed a positive signal; however, the intensity of the signal was much weaker when compared to P 1000 h. During the next cycle, the CL-I become the CL of the second generation (CL-II), which show increased necrosis. Between estrus and diestrus II of the next cycle, a large number of the CL-II cells (approximately 75%) were positive for IGFBP-3 and the signal was very strong in some groups of cells.(ABSTRACT TRUNCATED AT 400 WORDS)

Animals↗
PubMed1993

Insulin-like growth factor binding protein-4, -5 and -6 mRNAs in the human fetus: localization to sites of growth and differentiation?

The insulin-like growth factor binding proteins (IGFBP) modulate the regulatory actions of insulin-like growth factors (IGF) on fetal growth and development. We have determined the sites of IGFBP-4, -5 and -6 synthesis in 14-18 weeks gestation human fetal tissues using northern blot analysis and in situ hybridization to localize their mRNAs. IGFBP-4, -5 and -6 mRNAs were present in most fetal tissues at this gestational age. IGFBP-4 mRNA (2.3 kb) was widely expressed, most abundantly in kidney, stomach, intestine and lung and least in the liver. IGFBP-5 mRNA (6 kb) was in highest abundance in muscle, skin, stomach and intestine. IGFBP-6 mRNA (1.4 kb) was expressed with greatest abundance in the heart, muscle and skin and least in the liver. In situ hybridization confirmed the widespread occurrence of these mRNAs. The distribution of all three IGFBP mRNAs was similar in each tissue with variations in relative abundance between different regions. In general, IGFBP-4, -5 and -6 mRNAs were prevalent in regions of active cellular division and differentiation, suggesting that the binding proteins they encode specify the sites of IGF activity in the developing fetus. The widespread occurrence of their mRNAs suggests that, like IGFs, they are synthesized in multiple tissues in the fetus and have an autocrine or paracrine mode of action.

Blotting, Northern↗
PubMed1992

Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action.

BACKGROUND: The insulin-like growth factors (IGFs) play an important role in normal growth and development. Evidence suggests they may also regulate the growth of several cancer cell types. This regulation is mediated by interactions between the receptors and ligands. There is now ample evidence to suggest that these interactions are also influenced by extracellular IGF-binding proteins (IGFBPs). Six different IGFBPs have been cloned. Some species may act to inhibit the mitogenic effects of the IGFs. Since breast cancer cells are responsive to the IGFs, it is possible that regulated expression of the IGFBPs affects tumor growth. Furthermore, inhibitory binding proteins could be used as neutralizers of IGF action. PURPOSE: We conducted this study to fully characterize the expression and hormonal regulation of IGF-binding protein expression in human MCF-7 breast cancer cells and to test the ability of purified IGFBP-1 to inhibit IGF-I action. METHODS: We used ribonuclease protection assays and Western ligand blotting to examine IGFBP expression in MCF-7 cells. The effect of IGF-I, IGFBP-1, and 17 beta-estradiol on serum-free cell growth was also studied. RESULTS: MCF-7 cells expressed IGFBP-2, IGFBP-4, and IGFBP-5 RNA and protein. These cells are dependent on estrogen for growth. In short-term culture, IGF-I can substitute for estrogen. Concomitant addition of IGF-I and estrogen enhanced stimulation above the level achieved by either factor alone. Estrogen also increased IGFBP production, making it unlikely that the IGFBPs induced by estrogen in MCF-7 cells could function as major inhibitors of IGF action. In contrast, exogenous addition of IGFBP-1 could block IGF-I-induced mitogenesis; this effect was reversible by excess IGF-I. CONCLUSIONS: The studies suggest that cancer cell growth may be regulated by endogenous IGFBP expression. Furthermore, the exogenous addition of the IGFBP-1 blocked IGF-I action and potentially could be used as a pharmacologic inhibitor of IGF action.

Blotting, Western↗
PubMed1992

Differential expression of two distinct forms of mRNA encoding members of a dipeptidyl aminopeptidase family.

We have identified two cDNAs encoding dipeptidyl aminopeptidase-like proteins (DPPXs) in both bovine and rat brains that have different N-terminal cytoplasmic domains but share an identical transmembrane domain and a long C-terminal extracellular domain. In both species, one of the cDNAs encodes a protein (designated DPPX-S) of 803 amino acid residues with a short cytoplasmic domain of 32 amino acids, and the other cDNA encodes a protein (designated DPPX-L) with a longer cytoplasmic domain--the bovine cDNA encodes 92 amino acids and the rat cDNA encodes 88 amino acids. The membrane topology of DPPX-S and -L is similar to that of other transmembrane peptidases, and DPPX-S share approximately 30% identity and 50% similarity with reported yeast and rat liver dipeptidyl aminopeptidase amino acid sequences, suggesting that DPPX is a member of the dipeptidyl aminopeptidase family. DPPX-S mRNA is expressed in brain and some peripheral tissues including kidney, ovary, and testis; in contrast, DPPX-L mRNA is expressed almost exclusively in brain. No transcripts for either form are found in heart, liver, or spleen. In situ hybridization studies show that the two transcripts have different distributions in the brain. DPPX-L mRNA is expressed in limited regions of brain with the highest level of expression in the medial habenula. More widespread expression is seen for DPPX-S mRNA. The differential distribution of mRNAs for the DPPX-S and -L suggests that these proteins are involved in the metabolism of certain localized peptides and that the cytoplasmic domain may play a key role in determining the physiological specificity of DPPX.

Amino Acid Sequence↗
PubMed1992

Localization of the heparin binding site of follistatin.

To define the heparin-binding site of follistatin, the reduced and S-carboxymethylated recombinant human follistatin containing 288 amino acids was digested by Staphylococcus aureus V8. The digested product was subjected to sulfate cellufine column chromatography and the adsorbed peptide fragments eluted with a stepwise gradient of sodium chloride. The recovered column fractions were further purified by reversed-phase high-performance liquid chromatography (HPLC) and the HPLC peaks subjected to amino-terminal sequence analysis. All of the sulfate cellufine-retarded peptide fragments gave the same N-terminal amino acid sequence, which started at residue-68 of human follistatin, suggested that those fragments starting from residue-68 contain the heparin binding site. The multiple fragments might represent the oxidized, non-glycosylated or glycosylated forms of follistatin(68-113) resulting from the V8 digestion. A synthetic peptide corresponding to the region having the amino acid sequence 72-86 of follistatin was able to bind both heparin and sulfate cellufine, as well as compete with recombinant follistatin for binding to heparin. These findings further define the location of the heparin and heparan sulfate-binding site of follistatin at the basic amino acid-rich region comprising the amino acid sequence Lys75-Lys-Cys-Arg-Met-Asn-Lys-Lys-Asn-Lys-Pro-Arg86.

Amino Acid Sequence↗
PubMed1992

Gonadotropin and cAMP modulation of IGE binding protein production in ovarian granulosa cells.

Porcine granulosa cells (GC) produce insulin-like growth factor (IGF) binding protein (BP)-3 and IGFBP-2 in culture. A gonadotropin, follicle-stimulating hormone (FSH), dramatically inhibited GC production of these IGFBPs in control cultures and in cultures stimulated by insulin plus epidermal growth factor (EGF) or IGF-I plus EGF. Stimulators of adenylate cyclase (forskolin, cholera toxin) and a derivative of adenosine 3',5'-cyclic monophosphate (cAMP), 8-bromoadenosine 3',5'-cyclic monophosphate, inhibited IGFBP synthesis in a manner similar to FSH. In contrast, the antagonist of cAMP action, (R)-p-adenosine 3',5'-cyclic phosphorothioate [(R)-p-cAMPS], significantly stimulated production of IGFBP-3 and IGFBP-2 compared with controls. This stimulatory effect of (R)-p-cAMPS was counteracted by cotreatment with FSH in a dose-dependent manner. Finally, treatment of GC cultures with FSH plus 3-isobutyl-1-methylxanthine resulted in a significant reduction in cellular content of mRNA coding for IGFBP-3 with no change in IGFBP-2 mRNA. In summary, agents that elevate intracellular cAMP were found to mimic the effects of FSH on IGFBP production.

Animals↗
PubMed1992

Cyclic changes in insulin-like growth factor-binding protein-4 messenger ribonucleic acid in the rat ovary.

We have previously shown that the mRNA for insulin-like growth factor-binding protein-4 (IGFBP-4) is present in adult rat ovaries, being localized predominantly to granulosa cells of atretic follicles. Now we have considered the following questions. What class of atretic follicles expresses IGFBP-4 mRNA? How does IGFBP-4 mRNA expression change during the estrous cycle? In keeping with our earlier work, a strong hybridization signal for IGFBP-4 mRNA was present in subpopulations of follicles throughout the estrous cycle. In all cases, the hybridization signal was localized to granulosa cells. Among the various types of follicles, IGFBP-4 mRNA was present almost exclusively in atretic graafian (antral) follicles. Morphologically, the outer layer of granulosa cells was positive, while cells in the cumulus oophorous were negative. By Northern analysis and in situ hybridization, the levels of IGFBP-4 mRNA were found to change over the estrous cycle. At 1000 h on proestrus (before the LH/FSH surge), the hybridization signal was relatively weak, being restricted in some (but not all) atretic Graafian follicles. At 2000 h on proestrus, (after the LH/FSH surge), essentially all atretic Graafian follicles were strongly positive for the message. The pattern of hybridization was similar at 0200 h on estrus, but the signal was less intense. At 1000 h on estrus, the hybridization signal was variable, ranging from very strong to weak or undetectable in atretic follicles. At this stage, however, the highest levels of IGFBP-4 mRNA were measured by Northern analysis; interestingly, a strong signal became apparent in the stromal cells. On diestrous day 1, the message levels decreased, and the signal was restricted to some atretic follicles. On diestrous day 2, the hybridization signal was very weak. There was virtually no detectable IGFBP-4 mRNA in any healthy follicle. In summary, we found that IGFBP-4 mRNA is 1) not detected in healthy dominant follicles; 2) localized almost exclusively to atretic Graafian follicles, except on estrus when it also appears in stromal cells; 3) localized predominantly to the mural granulosa cells in atretic follicles; and 4) undergoes changes during the cycle, being most prominent around estrous morning. The possibility that IGFBP-4 plays a role in the cyclic destruction of cohort Graafian follicles at estrus, perhaps by mechanisms involving hormones, is discussed.

Animals↗
PubMed1992

Expression of messenger RNA for insulin-like growth factors and insulin-like growth factor binding proteins by experimental breast cancer and normal breast tissue in vivo.

We report the expression of insulin-like growth factors (IGFs) and their binding proteins (IGFBPs) by breast cancer cells and normal breast tissue in vivo. N-nitrosomethyl-urea (NMU)-induced rat mammary tumors synthesize mRNAs for IGF-II and IGFBP-2, -3, and -4. In contrast, normal lactating breast contains only IGFBP-2 and IGF-II messages; IGFBP-3 and -4 mRNAs are absent in this tissue. IGF-I and IGFBP-1 mRNAs are not expressed in either NMU tumors or in normal breast. This is the first report of in vivo expression of IGFBPs and IGF-II messages in breast tumors.

Animals↗
PubMed1992

Localization of insulin-like growth factor-binding protein-5 messenger ribonucleic acid in rat ovaries during the estrous cycle.

To investigate the potential role of insulin-like growth factor-binding protein-5 (IGFBP-5) in ovarian physiology, we employed in situ hybridization and Northern analysis to localize IGFBP-5 mRNA in rat ovaries during the estrous cycle. By Northern analysis, the mRNA was abundant at all stages of the cycle. Two species of mRNAs were detected, with sizes of 6.0 and 1.8 kilobases, respectively. The relative amounts of the two transcripts changed throughout the cycle. By in situ hybridization, IGFBP-5 mRNA was expressed in only a few cell types: 1) granulosa cells of some atretic follicles, 2) some secondary interstitial cells, 3) some corpora lutea, and 4) the surface epithelium. The levels of message in both the granulosa and secondary interstitial cells changed over the cycle. At 1000 h on proestrus (before the LH/FSH surge), the message was expressed in only a few follicles. Interestingly, all were small atretic preantral (200-250 microns) follicles. At 2000 h on proestrus (after the LH/FSH surge), the IGFBP-5 mRNA was more abundant; now almost every atretic preantral follicle showed a strong hybridization signal. At 0200 and 1000 h on estrus, the mRNA appeared for the first time in granulosa cells of some atretic antral follicles and in secondary interstitial cells. Hence, virtually all atretic follicles, preantral and antral, now showed IGFBP-5 gene expression. In contrast to that on proestrus and estrus, the hybridization signal on diestrous days 1 and 2 was much less prominent and was found in only a few atretic preantral follicles. Throughout the cycle, IGFBP-5 mRNA was evident in some corpora lutea, but it was not particularly prominent. Abundant IGFBP-5 mRNA was evident in the surface epithelium, and no change was detected over the cycle. Dominant follicles were devoid of IGFBP-5 mRNA. In conclusion, this paper presents the first evidence that the IGFBP-5 gene is expressed in the adult rat ovary. The IGFBP gene is expressed in a cell-specific manner, e.g. in atretic granulosa, secondary interstitial cells, corpora lutea, and the surface epithelium, and the stage of the cycle significantly affected message levels, especially in atretic granulosa and secondary interstitial cells around estrous morning. These findings suggest that IGBP-5 may be an autocrine/paracrine regulator of ovarian physiology, particularly in relation to preantral follicle atresia.

Animals↗
PubMed1992

Expression of insulin-like growth factor-binding protein-2 and -3 messenger ribonucleic acid in the porcine ovary: localization and physiological changes.

Insulin-like growth factor-binding protein (IGFBP)-2 and -3 are the most prevalent IGFBPs in porcine follicular fluid, as determined on ligand blots, but little is known about the localization and regulation of their synthesis in vivo. This study was designed to investigate the localization and cyclic regulation of the mRNA for these two IGFBPs in the porcine ovary, RNA was extracted from whole ovaries morphologically classified as immature, preovulatory, and luteal. Northern hybridization analysis of this RNA showed no significant difference in the expression of IGFBP-2 mRNA in these ovaries (OD for preovulatory, luteal, and immature ovaries, 0.076 +/- 0.01, 0.071 +/- 0.01, and 0.10 +/- 0.008/micrograms RNA, respectively). IGFBP-3 mRNA was not different in immature and preovulatory ovaries, but was 10-fold greater (P less than 0.025) in luteal ovaries. Northern analysis of RNA extracted from ovaries also showed no significant change in IGFBP-2 mRNA on days (d) 11, 16, and 21 of the estrous cycle. IGFBP-3 mRNA tended to decrease between d11-16 with the onset of luteal regression and was significantly decreased in d21 preovulatory ovaries to 22% of the values in d11 ovaries. Granulosa, thecal, and luteal cells were also analyzed for IGFBP mRNA. IGFBP-2 mRNA was most abundant in granulosa cells, lower in thecal cells, and lowest in luteal cells. No IGFBP-3 mRNA could be detected in granulosa cells, and luteal cells expressed 15- to 63-fold greater levels than thecal cells. These results show that IGFBP-2 and -3 mRNAs are expressed in specific ovarian cell types and that their expression appears to be independently regulated during the reproductive cycle. This provides further evidence for the importance of these proteins as paracrine/autocrine regulators of ovarian function.

Actins↗
PubMed1992

Expression of inhibin beta A and beta B, follistatin and activin-A receptor messenger ribonucleic acids in the rat seminiferous epithelium.

The expression of inhibin beta A and beta B subunits, follistatin, and activin-A receptor messenger RNA (mRNAs) in different stages of rat seminiferous epithelial cycle was analyzed by in situ hybridization in order to understand their role in the regulation of spermatogenesis. Inhibin beta A mRNA was expressed in Sertoli cells in a highly stage-specific manner. The mRNA levels started to accumulate in Sertoli cells at stage VIII of the cycle and were highly expressed during stages IX-XI. Follistatin mRNA expression was identical to that of inhibin beta A, while inhibin beta B mRNA was maximally expressed in Sertoli cells at stages XIII-III. Low expression was found in stages VII-VIII. Activin-A receptor mRNA was localized mainly in spermatogenic cells. Maximal expression was seen in late primary spermatocytes at stages XIII-XIV and in early round spermatids at stages I-IV. A low even expression by Sertoli cells was also seen. Inhibin beta A and follistatin mRNAs were coexpressed in stage IX-XI Sertoli cells, suggesting close interplay between these molecules. The pattern of inhibin beta B mRNA expression was similar to that of inhibin alpha-mRNA. Localization of activin-A receptor mRNA in spermatogenic cells suggests that activin may influence meiotic divisions and early spermiogenesis.

Activin Receptors↗
PubMed1992

Sweet's syndrome associated with subacute necrotizing lymphadenitis.

A 34-year-old man with Sweet's syndrome associated with subacute necrotizing lymphadenitis is reported. Histological examination of an erythematous, painful, cutaneous plaque revealed a dermal interstitial neutrophilic infiltrate. A biopsy specimen obtained from an inguinal lymph node showed granulomatous formation, consisting of histiocytes, with central necrosis in the paracortex and macrophages in the sinus. Although the causes of the two diseases remain obscure, this appears to be the first report of Sweet's syndrome associated with subacute necrotizing lymphadenitis.

Adult↗
PubMed1991

Structural motifs and potential sigma homologies in the large subunit of human general transcription factor TFIIE.

The general transcription factor TFIIE has an essential role in eukaryotic transcription initiation together with RNA polymerase II and other general factors. Human TFIIE consists of two subunits of relative molecular mass 57,000 (TFIIE-alpha) and 34,000 (TFIIE-beta) and joins the preinitiation complex after RNA polymerase II and TFIIF. Here we report the cloning and structure of a complementary DNA encoding a functional human TFIIE-alpha. TFIIE-alpha is necessary for transcription initiation together with TFIIE-beta, and recombinant TFIIE-alpha can fully replace the natural subunit in an in vitro transcription assay. The sequence contains several interesting structural motifs (leucine repeat, zinc finger and helix-turn-helix) and sequence similarities to bacterial sigma factors that suggest direct involvement in the regulation of transcription initiation.

Amino Acid Sequence↗